Published in final edited form as:

Bioorg Med Chem Lett. 2017 December 01; 27(23): 5179–5184. doi:10.1016/j.bmcl.2017.10.053.

Challenges in the development of an M₄ PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides

James C. Tarr^a, Michael R. Wood^{a,c}, Meredith J. Noetzel^{a,b}, Bruce J. Melancon^a, Atin Lamsal^{a,b}, Vincent B. Luscombe^a, Alice L. Rodriguez^a, Frank W. Byers^a, Sichen Chang^a, Hyekyung P. Cho^a, Darren W. Engers^a, Carrie K. Jones^{a,b}, Colleen M. Niswender^{a,b,e}, Michael W. Wood^d, Nicholas J. Brandon^d, Mark E. Duggan^d, P. Jeffrey Conn^{a,b,e}, Thomas M. Bridges^{a,b}, and Craig W. Lindsley^{a,b,c}

^aVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

^bDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

^cDepartment of Chemistry, Vanderbilt University, Nashville, TN 37232, USA

^dNeuroscience Innovative Medicines, Astra Zeneca, 141 Portland Street, Cambridge, MA 02139, USA

^eVanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA

Abstract

Herein we describe the continued optimization of M₄ positive allosteric modulators (PAMs) within the 5-amino-thieno[2,3-*c*]pyridazine series of compounds. In this letter, we disclose our studies on tertiary amides derived from substituted azetidines. This series provided excellent CNS penetration, which had been challenging to consistently achieve in other amide series. Efforts to mitigate high clearance, aided by metabolic softspot analysis, were unsuccessful and precluded this series from further consideration as a preclinical candidate. In the course of this study, we found that potassium tetrafluoroborate salts could be engaged in a tosyl hydrazone reductive cross coupling reaction, a previously unreported transformation, which expands the synthetic utility of the methodology.

Graphical Abstract

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

M₄; Muscarinic acetylcholine receptor; Positive Allosteric modulator (PAM); Schizophrenia; Azetidine

Following demonstration of clinical efficacy by xanomeline, a pan muscarinic acetylcholine receptor (mAChR) agonist, to treat multiple symptom clusters of schizophrenia,^{1–3} selective activation of the mAChR subtype M₄ has emerged as a promising approach for the treatment of numerous CNS disorders.^{4–26} While achieving mAChR subtype selectivity at the highly conserved orthosteric acetylcholine binding site has remained challenging, an alternative strategy of targeting an allosteric site with less evolutionary pressure towards conservation via positive allosteric modulators (PAMs) has met with success. This allosteric approach has not only proven to be a mechanism to potentiate the response of the M₄ receptor to acetylcholine, but also to obtain excellent selectivity across the mAChR subtypes. Our group and others have reported a number of potent, selective M₄ PAMs which have shown efficacy in preclinical animal models of schizophrenia (Figure 1).^{4–7,11,14,22–26}

Recently, our group reported the discovery of VU0476406 (**5**),²⁵ which displayed excellent potency (hM₄ EC₅₀ = 91 nM, ACh_{Max} = 74±3%), clean ancillary pharmacology (including high mAChR subtype selectivity), and an early DMPK profile suitable for evaluation as a preclinical candidate (CL_p = 1.6 mL/min/kg, *t*_{1/2} = 2.7 h, K_p = 0.11, K_{p,uu} = 1.2). One of the key setbacks found during the characterization of VU0476406, which precluded its advancement into IND-enabling studies, was its low solubility (<0.5 µM at pH 7.4) and solubility-limited oral absorption in dog (%F = 4.7 as HCl salt). An x-ray crystal structure of **5** showed extensive hydrogen bonding and π -stacking between neighboring molecules in the lattice, which likely contributed to the compound's poor aqueous solubility. We hypothesized that disruption of both the hydrogen bonding and π -stacking would be beneficial. Replacement of the benzyl linker with a saturated cyclic moiety would impart additional sp³ character and could disrupt the planarity of the compounds which may impede π -stacking. Additionally, removal of the amide N-H could also disrupt the hydrogen bonding network, which may improve the solubility and absorption, as well as possibly mitigate P-gp efflux which had limited CNS exposure in some 5-amino-thieno[2,3-*c*]pyridazine analogs. Unfortunately, in examples across several different amide series, replacement of the amide NH with a methyl group resulted in a dramatic loss of human M₄ (hM₄) potency (data not shown). However, given our success in employing small, cyclic diamine linkers at the amide portion of our compounds,²⁴ we turned our attention to examining cyclic amines linked through an endocyclic amine to the thieno[2,3-*c*]pyridazine core to furnish a library of tertiary amides.

We initially examined a variety of 4, 5, and 6-membered cyclic amines and diamines to assess the feasibility of this strategy. Despite finding numerous potent and efficacious secondary exocyclic amides representing a variety of ring sizes and substitution patterns, the majority of endocyclic tertiary amides examined were either inactive or only weakly active (Figure 3). Fortunately, in our screen we found that substitution at the 3-position of the azetidine amides provided a substantial boost in potency. In order to synthesize 3-aryl substituted azetidines, we relied on either a Negishi reaction²⁸ starting from commercially available 1-Boc-3-iodoazetidine or a metal-free reductive cross coupling between a tosyl hydrazone and boronic acid (Scheme 1).^{29,30} The operational simplicity (air and moisture stable intermediates amenable to isolation, purification, and storage) and substrate tolerance of the reductive cross coupling allowed us to rapidly and efficiently explore the SAR of this series. In the course of coupling tosyl hydrazone azetidine with boronic acid partners, we sought to investigate the ability of the azetidine tosyl hydrazones to engage BF₃K salts (Table 1). In a small screen of BF₃K salts, we found that four out of five examined provided the desired coupled product. While the simple allyl trifluoroborate salt failed to couple, substituted vinyl, aryl, and heteroatom containing BF₃K salts afforded the desired product. Although the yields were modest, we were able to obtain them with no modification or optimization of the original protocol,

Conditions: a) Zn, TMSCl, 1,2-dibromoethane, ArX, Pd(PPh₃)₄ b) TFA, DCM, r.t c) 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid, HATU, DIPEA, DMF, r.t d) TsNHNH₂, 1,4-dioxane, 80 °C e) RB(OH)₂, K₂CO₃, 1,4-dioxane, 110 °C.

demonstrating the general utility of this reaction. To the best of our knowledge, this represents the first reported example whereby a BF₃K salt has been used to engage the tosyl hydrazone in a reductive cross coupling, allowing for the preparation of analogs for which the boronic acid may not be stable.

The 3-position of the azetidine tolerated aryl (**10a**, **10d-10l**), aliphatic (**10b**), and heteraryl (**10c**) substitution (Table 2). One of the most potent analogs prepared was unsubstituted phenyl group **10a** (hM₄ EC₅₀ = 72 nM, ACh_{Max} = 65±3%). As frequently observed with PAM SAR, substitution on the aryl ring could result in dramatic and unpredictable differences in potency. Introduction of a methyl group at either the 2-, 3-, or 4-position (**10d-10f**) resulted in a fairly uniform loss of potency (4–7-fold); however, a methoxy substituent at the 4-position (**10i**) resulted in a modest ~3.5-fold loss in potency while the meta-substituted analog gave >100-fold loss in potency (**10h**). As we have previously observed in M₄ PAM SAR, fluoro substituents were well tolerated, especially the 3- and 4-position (**10k** and **10l**). Replacement of the fluorine with other halogens resulted in a complete loss of hM₄ activity (**10m**, **10n**). Saturation of the phenyl ring (**10b**) led to a modest decrease in potency (hM₄ EC₅₀ = 178 nM, ACh_{Max} = 54 ± 12), as did heteroaryl substitution (**10c**) (hM₄ EC₅₀ = 200 nM, ACh_{Max} = 78 ± 7).

In order to further evaluate this new amide series, **10a**, **10b**, **10k** and **10l** were evaluated for mAChR subtype selectivity and *in vitro* DMPK assays. Compound **10a** was subjected to full subtype selectivity screening and found to possess excellent selectivity for hM₄ over other subtypes (hM_{1-3,5} EC₅₀ > 10 μM). Compound **10k** and **10l** were counter screened against

hM₂, and **10l** was found to be inactive. While **10k** was active at hM₂ (EC₅₀ = 2.10 μM), it only weakly potentiated the ACh response (ACh_{Max} = 38%). In contrast to a number of other series with the thieno[2,3-*c*]pyridazine core, **10a** was ~2-fold more potent at hM₄ compared to rat M₄ (rM₄; data not shown). When assessed for CNS penetration, all four compounds were found to have high brain distribution in rat (**10a** K_p = 2.6, K_{p,uu} = 2.1; **10b** K_p = 8.46, K_{p,uu} = 0.71; **10k** K_p = 2.1, K_{p,uu} = 0.92, **10l** K_p = 2.3, K_{p,uu} = 1.3). As a class, the tertiary azetidines appear to address one of the major challenges associated with the previously reported secondary azetidine series, which suffered from P-gp efflux and low CNS exposure, requiring an extensive SAR campaign to address these parameters. Unfortunately, all four compounds exhibited high predicted clearance in both rat and human (**10a** CL_{hep} = 64 (r), 20 (h) mL/min/kg; **10b** CL_{hep} = 65 (r), 20 (h) mL/min/kg; **10k** CL_{hep} = 56 (r), 19 (h) mL/min/kg; **10l** CL_{hep} = 56 (r), 19 (h) mL/min/kg) based on hepatic microsomal CL_{int} data using the well-stirred model (binding terms excluded).

To address the putative high clearance in this series of compounds, metabolic softspot analysis was performed using rat hepatic microsomal incubations, which identified NADPH-dependent hydroxylation of the azetidine ring as the principle pathway of metabolism (data not shown). Based on this finding, we sought to improve the metabolic stability by blocking the benzylic site on the azetidine ring. Synthesis of these compounds was accomplished by addition of the appropriate Grignard or organolithium reagent into 1-Boc azetidinone, followed by alkylation with MeI or fluorination of the resultant alcohol with DAST (Scheme 2). The Boc group was then cleaved with TFA and the azetidine connected to the core via a HATU coupling, analogous to the route described in Scheme 1. In general, the introduction of geminal substituents at the 3-position resulted in a loss of potency, with -OH (**11a**) and -OMe (**11b**) resulting in a ~10-fold and ~6-fold loss of potency, respectively. Both of these substitutions also resulted in a marked decline in the compounds' efficacy in potentiation of the ACh response. Replacement of the benzylic hydrogen with fluorine was better tolerated (**11c-f**), especially with regards to ACh_{Max}; however, the EC₅₀s obtained from these compounds were still ~5-fold weaker than the best analogs bearing a hydrogen at the benzylic position. Additionally, all compounds tested in which the benzyl site was blocked were still found to possess predicted rat and human clearance near or at hepatic blood flow rates. Ultimately, metabolite identification efforts found that the primary pathway for metabolism was oxidation on the azetidine ring irrespective of the fluorine atom at the benzylic site.

With these data in hand, additional strategies were also examined for minimizing the clearance of the 3-aryl azetidine analogs. We examined introduction of a methyl group at the 2-position of the azetidine, which we hoped may reduce oxidation on the azetidine ring. Starting from commercially available tert-butyl 2-methyl-3-oxoazetidine-1-carboxylate and following the synthetic route described in Scheme 1, analogs **12a** and **12b** were prepared. Both compounds suffered from weaker potency (EC₅₀ = 1510, 1455 nM, respectively), but also an impaired ability to reach full potentiation of the hM₄ receptor (ACh_{Max} = ~45%).

Introduction of a spiro-pyrrolidine ring to the azetidine amide afforded analogs **13a** and **13b**. This substitution also led to a decrease in hM₄ potency relative to **10a** (EC₅₀ = 324 and 500 nM, respectively). Furthermore, both analogs still suffered from high predicted clearance

(CL_{hep} = 49 and 56 mL/min/kg, respectively). After being unable to identify substitutions to either the 3-position substituent or the azetidine ring that would allow us to address the high clearance associated with this class of compounds yet still maintain reasonable potency, **10a** was evaluated in a rat amphetamine-induced hyperlocomotion (AHL) model of antipsychotic efficacy. Despite its high predicted clearance, at a 30 mg/kg oral dose **10a** was still able to achieve 32% reversal of AHL.

In summary, we have described the synthesis and biological evaluation of a novel series of tertiary azetidine amides within the 5-amino-thieno[2,3-*c*]pyridazine class of M₄ PAMs. In the synthesis of these compounds, we were able to utilize a reductive cross coupling between azetidinyI tosyl hydrazones and boronic acids, and found that this methodology could be extended to trifluoroboronate salts as well. This new series of azetidine amides was promising because its members generally provided excellent CNS exposure and possessed a preference for activity at hM₄ over rM₄, two trends that had been challenging to overcome in other series studied. Despite suffering from high predicted clearance, which we were unable to alleviate with substitutions at either the 3-position substituent or the azetidine ring itself, compound **10a** was able to achieve 32% reversal in a rodent AHL model. Future studies aimed at achieving potent molecules with a suitable disposition are currently underway and will be reported in due course.

Conditions: a) RMgBr or RLi, THF, 0 °C b) MeI, K₂CO₃, DMF c) DAST, DCE

Acknowledgments

The authors would like to thank NIH (U01MH087965, Vanderbilt, NCDDG). We also thank William K. Warren, Jr. and the William K. Warren Foundation who funded the William K Warren, Jr. Chair in Medicine (to C.W.L.).

References

1. Bodick NC; Offen WW; Levey AI; Cutler NR; Gauthier SG; Satlin A; Shannon HE; Tollefson GD; Rasmussen K; Bymaster FP; Hurley DJ; Potter WZ; Paul SM Arch. Neurol 1997, 54, 465–473. [PubMed: 9109749]
2. Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dube S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC Am. J. Psychiatry 2008, 165, 1033–1039. [PubMed: 18593778]
3. Lieberman JA; Javitch JA; Moore H Am. J. Psychiatry 2008, 165, 931–936. [PubMed: 18676593]
4. Chan WY; McKinize DL; Bose S; Mitchell SN; Witkins JM; Thompson RC; Christopoulos A; Birdsall NJ; Bymaster FP; Felder CC Proc. Natl. Acad. Sci. USA 2008, 105, 10978–10983. [PubMed: 18678919]
5. Leach K; Loiancono RE; Felder CC; McKinize DL; Mogg A; Shaw DB; Sexton PM; Christopoulos A Neuropsychopharmacology 2010, 35, 855–869. [PubMed: 19940843]
6. Brady A; Jones CK; Bridges TM; Kennedy PJ; Thompson AD; Breininger ML; Gentry PR; Yin H; Jadhav SB; Shirey J; Conn PJ; Lindsley CWJ Pharm. & Exp. Ther 2008, 327, 941–953.
7. Byun NE; Grannan M; Bubser M; Barry RL; Thompson A; Rosanelli J; Gowrishnakar R; Kelm ND; Damon S; Bridges TM; Melancon BJ; Tarr JC; Brogan JT; Avison MJ; Deutch AY; Wess J; Wood MR; Lindsley CW; Gore JC; Conn PJ; Jones CK Neuropsychopharmacology 2014, 39, 1578–1593. [PubMed: 24442096]
8. Farrell M; Roth BL Neuropsychopharmacology 2010, 35, 851–852. [PubMed: 20145632]
9. Jones CK; Byun N; Bubser M Neuropsychopharmacology 2012, 37, 16–42. [PubMed: 21956443]
10. Shirey JK; Xiang Z; Orton D; Brady AE; Johnson KA; Williams R; Ayala JE; Rodriguez AL; Wess J; Weaver D; Niswender CM; Conn PJ Nat. Chem. Bio 2008, 4, 42–50. [PubMed: 18059262]

11. Le U; Melancon BJ; Bridges TM; Utley TJ; Lamsal A; Vinson PN; Sheffler DJ; Jones CK; Morrison R; Wood MR; Daniels JS; Conn PJ; Niswender CM; Lindsley CW Hopkins CR Bioorg. Med. Chem. Lett 2013, 23, 346–350. [PubMed: 23177787]
12. Kennedy JP; Bridges TM; Gentry PR; Brogan JT; Brady AE; Shirey JK; Jones CK; Conn PJ; Lindsley CW ChemMedChem. 2009, 4, 1600–1607. [PubMed: 19705385]
13. Salovich JM; Sheffler DJ; Vinson PN; Lamsal A; Utley TJ; Blobaum AL; Bridges TM; Le U; Jones CK; Wood MR; Daniels JS; Conn PJ; Niswender CM; Lindsley CW; Hopkins CR Bioorg. Med. Chem. Lett 2012, 22, 5084–5088. [PubMed: 22738637]
14. Bubser M; Bridges TM; Thorbeck DD; Gould RW; Grannan M; Noetzel MJ; Niswender CM; Daniels JS; Melancon BJ; Tarr JC; Wess J; Duggan ME; Brandon NJ; Dunlop J; Wood MW; Wood MR; Lindsley CW; Conn PJ; Jones CK ACS Chem. Neurosci 2014, 5, 920–942. [PubMed: 25137629]
15. Smith E; Chase P; Niswender CM; Conn PJ; Lindsley CW; Madoux F; Acosta M; Scampavia L; Spicer T; Hodder PJ Biomol. Screening 2015, 20, 858–868.
16. Wood MR; Noetzel MJ; Tarr JC; Rodriguez AL; Lamsal A; Chang S; Foster JJ; Smith E; Hodder PS; Engers DW; Niswender CM; Brandon NJ; Wood MW; Duggan ME; Conn PJ; Bridges TM; Lindsley CW Bioorg. Med. Chem. Lett 2016, 26, 4282–4286. [PubMed: 27476142]
17. Wood MR; Noetzel MJ; Engers JL; Bollinger KA; Melancon BJ; Tarr JC; Han C; West M; Gregro AR; Lamsal A; Chang S; Ajmera S; Smith E; Chase P; Hodder PS; Bubser M; Jones CK; Hopkins CR; Emmittle KA; Niswender CM; Wood MW; Duggan ME; Conn PJ.; Bridges TM; Lindsley CW Bioorg. Med. Chem. Lett 2016, 26, 3029–3033. [PubMed: 27185330]
18. Szabo M; Huynh T; Valant C; Lane JR; Sexton PM; Christopoulos A; Capuano B MedChemComm. 2015, 6, 1998–2003.
19. Huynh T; Valant C; Crosby IT; Sexton PM; Christopoulos A; Capuano B ACS Chem. Neurosci 2015, 6, 1592–1599.
20. Croy CH; Schober DA; Xiao H; Quets A; Christopoulos A; Felder CC Mol. Pharmacol 2014, 86, 106–115. [PubMed: 24807965]
21. Huynh T; Valant C; Crosby IT; Sexton PM; Christopoulos A; Capuano B J. Med. Chem 2013, 56, 1592–1599.
22. Wood MR; Noetzel MJ; Poslusey MS; Melancon BJ; Tarr JC; Lamsal A; Chang S; Luscombe VB; Weiner RL; Cho HP; Bubser M; Jones CK; Niswender CM; Wood MW; Engers DW; Brandon NJ; Duggan ME; Conn PJ; Bridges TM; Lindsley CW Bioorg. Med. Chem. Lett 2017, 27, 171–175.
23. Wood MR; Noetzel J; Melancon BJ; Poslusney MS; Nance KD; Hurtade MA; Luscombe VB; Weiner RL; Rodriguez AL; Lamsal A; Chang S; Bubser M; Blobaum AL; Engers DW; Niswender CM; Jones CK; Brandon NJ; Wood MW; Duggan ME; Conn PJ; Bridges TM; Lindsley CW ACS Med. Chem. Lett 2017, 8, 233–238. [PubMed: 28197318]
24. Tarr JC; Wood MR; Noetzel MR; Bertron J; Weiner RL; Rodriguez AL; Lamsal A; Byers FW; Chang S; Cho HP; Jones CK; Niswender CM; Wood MW; Brandon NJ; Duggan ME; Conn PJ; Bridges TM; Lindsley CW Bioorg. Med. Chem. Lett 2017, In press.
25. Melancon BJ; Wood MR; Noetzel MJ; Nance KD; Engelberg EM; Han C; Lamsal A; Chang S; Cho HP; Byers FW; Bubser M; Jones CK; Niswender CM; Wood MW; Engers DW; Wu D; Brandon NJ; Duggan ME; Conn PJ; Bridges TM; Lindsley CW Bioorg. Med. Chem. Lett 2017, 11, 2296–2301.
26. Pancani T; Foster DJ; Bichell T; Bradley E; Bridges TM; Klar R; Daniels JS; Jones CK; Bowman AB; Lindsley CW; Xiang Z; Conn PJ Proc. Natl. Acad. Sci. USA, 2015, 112, 14078–14083. [PubMed: 26508634]
27. Shen W; Plotkin JL; Francardo V; Ko WKD; Xie Z; Li Q; Fieblinger T; Wess J; Neubig RR; Lindsley CW; Conn PJ; Greengrad P; Bezard E; Cenci MA; Surmeier DJ Neuron 2015, 88, 762–773. [PubMed: 26590347]
28. Haas D; Hammann JM; Greiner R; Knochel P ACS Catal. 2016, 6, 1540–1552.
29. Barluenga J; Tomas-Gamasa M; Aznar F; Valdes C Nature Chemistry 2009, 1, 494–499.
30. Allwood DM; Blakemore DC; Brown AD; Ley SV J. Org. Chem 2014, 79, 328–338. [PubMed: 24304206]
31. VU0467485 (Ref. 23) was included as a positive control during each experiment.

Figure 1.
Structures of previously reported M₄ PAMs

Figure 2.

a) X-ray diffraction of **5** b) rationale for tertiary amide design

tertiary amines

7e: 4-fluoro

7g: 3-phenyl
7h: 4-phenyl

tertiary diamines

R = acyl, carbamate, sulfonyl, alkyl

Figure 3.

Cyclic tertiary amides generated on thieno-[2,3-*c*]pyridazine core. Majority of examples hM₄ EC₅₀ > 2 μM.

Scheme 1.
Synthesis of tertiary azetidine analogs

Scheme 2.

Synthesis of azetidines with benzylic hydrogen removed

Table 1.

Reductive cross coupling with trifluoroborate salts

Entry	RBF ₃ K	Yield (%)
1		NDP
2		31
3		29
4		25
5		28

Table 2.

Analogues derived from 3-substituted azetidines

Cmpd	R	hM ₄ EC ₅₀ (nM) ^a [% ACh Max ±SEM]	hM ₄ pEC ₅₀ (±SEM)
10a		72 [65±3]	7.14±0.18
10b		178 [54±12]	6.75±0.16
10c		200 [78±7]	6.70±0.13

<p style="text-align: center;">10</p>			
Cmpd	R	hM ₄ EC ₅₀ (nM) ^a [% ACh Max ±SEM]	hM ₄ pEC ₅₀ (±SEM)
10d		457 [72±7]	6.34±0.04
10e		851 [83±6]	6.07±0.06
10f		1096 [82±4]	5.96±0.11
10g		2090 [54±7]	5.64±0.15

<p style="text-align: center;">10</p>			
Cmpd	R	hM ₄ EC ₅₀ (nM) ^a [% ACh Max ±SEM]	hM ₄ pEC ₅₀ (±SEM)
10h		>10,000 [N.D.]	N.D.
10i		331 [94±7]	6.48±0.12
10j		407 [75±8]	6.39±0.03
10k		57 [83±9]	7.24±0.20
10l		151 [80±7]	6.82±0.13

<p style="text-align: center;">10</p>			
Cmpd	R	hM ₄ EC ₅₀ (nM) ^a [% ACh Max ±SEM]	hM ₄ pEC ₅₀ (±SEM)
10m		>10,000 [N.D.]	N.D.
10n		>10,000 [N.D.]	N.D.

^aCalcium mobilization assays with hM₄/Gq15-CHO cells performed in the presence of an EC₂₀ fixed concentration of acetylcholine; values represent means from three (*n*=3) independent experiments performed in triplicate.³¹

Table 3.

Analogues of 3-substituted azetidines with benzylic position blocked

11				
Cmpd	R	X	hM ₄ EC ₅₀ (nM) ^a [% ACh Max ±SEM]	hM ₄ pEC ₅₀ (±SEM)
11a		OH	1047 [30±4]	5.98±0.04
11b		OMe	417 [36±2]	6.38±0.08
11c		F	447 [67±3]	6.38±0.08

<p style="text-align: center;">11</p>				
Cmpd	R	X	hM ₄ EC ₅₀ (nM) ^a [% ACh Max ±SEM]	hM ₄ pEC ₅₀ (±SEM)
11d		F	2240 [78±1]	5.65±0.23
11e		F	316 [85±12]	6.50±0.23
11f	-Me	F	363 [98±12]	6.44±0.07

^aCalcium mobilization assays with hM₄/Gq15-CHO cells performed presence of an EC₂₀ fixed concentration of acetylcholine; values in the represent means from three (*n*=3) independent experiments performed in triplicate.

Table 4.

Azetidine analogs to address high clearance

Cmpd	R	hM ₄ EC ₅₀ (nM) ^a [% ACh Max ±SEM]	hM ₄ pEC ₅₀ (±SEM)
12a		1510 [45±3]	5.82±0.24
12b		1455 [45±2]	5.84±0.15
12c		324 [57±0]	6.49±0.07
12d		500 [53±1]	6.39±0.22

^aCalcium mobilization assays with hM₄/Gq15-CHO cells performed in the presence of an EC₂₀ fixed concentration of acetylcholine; values represent means from three (*n*=3) independent experiments performed in triplicate.